Agalsidase beta

阿加糖酶β

Report date: 2022/01/14 13:23:58
First In Class

Base Information

Drug NameAgalsidase beta
Drug Alias NameAgalsidase β半乳糖苷酶βagalsidase betaagalsidasum beta法布赞 +[7] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of Actionglycosphingolipid hydrolysis activatorsglobotriaosylceramide (GL-3) hydrolysisα-Galactosidase replacements
TargetsGlycosphingolipid
Therapy Area/IndicationsRenal Insufficiency, ChronicFabry Disease
Global Approved IndicationsFabry Disease
Approved Indications in ChinaFabry Disease
Original Approved Country/TerritoryEU
Original Approved Date2001/08/03
Country/TerritoryCzechiaCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesBio Sidus SaSanofiGenzyme Europe Bv +[4] 
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsRenal Insufficiency, Chronic

Other Information

ATC CodeA16AB04
Related LinksWikipediaDrugBankKEGG